| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Accent Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Avenzo Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $445.85M | Series B | 9/22/2025 | $60M | $616.96M | $2.22 | OrbiMed, SR One, Longwood Fund, Foresite Capital, Lilly Asia Ventures, Surveyor Capital, NEA, Deep Track Capital, Sofinnova Investments, Sands Capital, INCE Capital, TF Capital, Delos Capital, Quan Capital | ||||
 | BigHat Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $104.3M | Series B | 7/20/2022 | $80M | $249.63M | $9.24 | Section 32, Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, GRIDS Capital, Andreessen Horowitz, 8VC, AME Cloud Ventures | ||||
 | BioTissue | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Blackrock Neurotech | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Butterfly Network | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $370.76M | Series D | 9/27/2018 | $250M | $1.28B | $10.27 | Bill & Melinda Gates Foundation, Fidelity Investments, Fosun Pharma, Jamaie Dinan | ||||
 | Capsule | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $180.56M | Series E | 2/13/2023 | $100M | $458.12M | $2.93 | Cox Enterprises, SeedFord Partners | ||||
 | CG Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $510.76M | Series F | 8/2/2023 | $105.02M | $615.24M | $1.29 | Foresite Capital, TCGX, Avidity Partners, BVF Partners, Janus Henderson Investors, Acorn Bioventures, Ally Bridge Group, Decheng Capital, Longitude Capital, Malin Corporatoin, RA Capital Management | ||||
 | Click Therapeutics | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $167.96M | Series D-1 | 4/9/2026 | $25M | $567.95M | $6.55 | Boehringer Ingelheim | ||||
 | ConcertAI | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Curative | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $8.79M | Series A-7 | 9/23/2020 | $2.86M | $37.8M | $0.04 | DCVC, Refactor Capital, Chris Anderson | ||||
 | EndoQuest Robotics | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $207.22M | Series D-2 | 7/14/2025 | $30.74M | $316.22M | $0.80 | Crescent Enterprises, Dr. Fred Moll, Puma Venture Capital, UTHealth Houston | ||||
 | Frontier Medicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $255.5M | Series C | 6/25/2024 | $100M | $438.18M | $2.34 | Deerfield Management Company, Droia Ventures, Galapagos NV, DCVC, MPM Capital, RA Capital Management, Deep Track Capital, ArrowMark Partners | ||||
 | Genesis Molecular AI | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $150.01K | -- | 1 | -- | Not available | -- | -- | $340.28M | Series B-3 | 5/20/2026 | $40M | $806.79M | $9.33 | Incyte | ||||
 | HeartFlow | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $755.52M | Series F | 4/6/2023 | $174.86M | $546.5M | $2.85 | Bain Capital, Janus Henderson Investors, Baillie Gifford, Capricorn Investment Group, Hayfin Capital Management, HealthCor, Martis Capital, USVP, Wellington Management | ||||
 | Impress | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Iterative Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $272.32M | Series C | 4/30/2026 | $77.01M | $1.3B | $26.32 | Intrepid Growth Partners, GV, EDBI, Insight Partners, Obvious Ventures | ||||
 | Kindbody | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $200.00K | -- | 1 | Not available | -- | -- | $1.59B | Series E-1 | 12/31/2024 | $79.37M | $420.77M | $3.73 | Undisclosed Investors | ||||
 | Noctrix Health | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Nusano | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $449.68M | Series D-1 | 4/21/2026 | $155M | $630.01M | $1.25 | Undisclosed Investors | ||||
 | Obsidian Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $325.04M | Series C | 4/3/2024 | $160.5M | $507.38M | $1.90 | Wellington Management, Foresite Capital, Janus Henderson Investors, Novo Holdings, Paradigm BioCapital, RTW Investments, T. Rowe Price Associates, Woodline Partners, Atlas Venture, Blue Owl Capital, Bristol Myers Squibb, Deep Track Capital, Logos Capital, RA Capital Management, TCG Crossover Management, Samsara, Surveyor Capital | ||||
 | Octave | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $91.68M | Series C-3 | 2/1/2024 | $5M | $208.27M | $1.95 | Felicis | ||||
 | OSSIO | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Owkin | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $279.77M | Series B-1 | 6/8/2022 | $50M | $1.46B | $45.70 | Bristol Myers Squibb | ||||